Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
20 Apr 2024 //
PHARMABIZ
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran
07 Apr 2024 //
BUSINESSWIRE
Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran
20 Mar 2024 //
BUSINESSWIRE
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
06 Mar 2024 //
BIOPHARMA DIVE
Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran
07 Sep 2023 //
BUSINESSWIRE
Roche enters partnership with Alnylam for hypertension therapy
25 Jul 2023 //
REUTERS